中药药物性肝损伤的重新评价  

Re-evaluation of drug-induced liver injury of traditional Chinese medicine

作　　者：钱董文 方忠宏[2] 吕小群[2] 刘玉娟[2] QIAN Dong-wen;FANG Zhong-hong;LYU Xiao-qun;LIU Yu-juan(Department of Pharmacy,Minhang District Central Hospital,Fudan University,Shanghai 201100,China;Department of Pharmacy,Jinshan Hospital,Fudan University,Shanghai 201508,China)

机构地区：[1]复旦大学附属闵行区中心医院药剂科,上海201100 [2]复旦大学附属金山医院临床药学室,上海201508

出　　处：《中华中医药杂志》2020年第9期4407-4409,共3页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：上海市临床药学重点学科建设项目(No.2019-1229)。

摘　　要：调研国内关于中药药物性肝损伤(DILI)的报告,阐明在中药DILI中存在的误解与错误。分析国内的中药DILI报告内容,论证报告DILI病因的复杂性,非单一的中药,表明目前国内中药DILI报告中存在的不足、误解、误传,及中药不该承受的诸多非议。现在中药DILI的报告存在的疑点很多,而中药DILI所占百分比的多变性,恰好说明了这一点。在现有中药DILI的报告中,通常没有中药相关的鉴定、鉴别信息,或中药材来源的信息证据。中药DILI的报告急需规范,中药DILI需要再评价。Investigate reports of drug-induced liver injury(DILI)of traditional Chinese medicine(TCM),and clarify the misunderstandings and errors in DILI reports of TCM.By analyzing the content of DILI reports of TCM,the complexity and diversity of DILI causes,generally not the single cause of TCM were presented.It shows that the current DILI reports of TCM have deficiencies,misunderstandings,misinformation,and TCM has endured many unsuitable criticisms.There are too many doubts in DILI reports of TCM,and the great percentage variability of DILI of TCM illustrates this standpoint.In published DILI reports of TCM,there is usually no identification information of TCM,and source of TCM.The DILI reports of TCM need urgently be standardized,and re-evaluated.

关 键 词：药物性肝损伤 中药 中西药合用 

分 类 号：R285.6[医药卫生—中药学]